Biotech Daily covers the major announcements from ASX-listed biotech companies as well as developments in government policy and regulation.
Marc Sinatra holds a BSc (Hons, Genetics) from the University of Melbourne and an MBA from the Melbourne Business School. He is a keen observer of the biotechnology sector and formerly worked for Bio-21 as a business development manager.
Each month, Marc provides a financial analysis of the Australian biotechnology industry, focusing on a specific company’s intellectual property, stage of development, balance sheet and share price performance.
Each company report is a detailed snapshot of the financial state of the enterprise with Marc Sinatra’s recommendation.
Marc also comments on topical issues as and when they occur in his ongoing Bioguide Brief Notes - see below.
Marc Sinatra's Bioguide Brief Notes:
Topical analyses of companies, mergers
and issues facing the sector
May 25, 2011
Why I Wasn't Holding Pharmaxis
Apr 4, 2011
Cellestis' Playing The Ball, Not The Man, Pays Off
Apr 1, 2011
Bouquets For Biota, Bionomics
Valeant Bid Unlikely To Affect Chemgenex
Mar 29, 2011
Chemgenex Going Down - $5.50 ... $2.90 ... 70c
Mar 28, 2011
Avexa's ATC Harder to Kill Than A Cockroach
Dec 8, 2010
Cephalon Swoops On Mesoblast - Good For All
Dec 6, 2010
Bioniche Blue Sky Over Solid Ground
Dec 6, 2010
Chemgenex Revalued From $5.50 To $2.90, Maybe
Dec 3, 2010
Dr George Jessup Starts-Up Bionomics
Nov 24, 2010
Acrux Joins The Revenue PositiveRare Breeds
Sep 13, 2010
Broadvector's 'Very Reasonable' IPO
Sep 13, 2010
Biota, Daiichi Sankyo & A New Generation 'Flu Drug
Sep 9, 2010
Novogen To Be Cash Flow Positive - Duh, Wuh?
Aug 20, 2010
Chemeq - It's Still Alive!
Aug 18, 2010
Phylogica - Is Deal, Is Good
Aug 10, 2010
Acrux, Calzada, Avexa & Looking After Number 1
Jul 8, 2010
Axeva Investors Need To Face Facts
Jun 23, 2010
Pharmaxis 'Missed By That Much' Or Did It?
Jun 2, 2010
Novogen Joins The Failed Phase III Club
May 12, 13, 2010
Mesoblast Takes Angioblast - Victory For All
May 10, 2010
Avexa's Apricitabine - A Busted Flush
Apr 21, 2010
Biota Loses Another Collaborator
Apr 12, 2010
Chemgenex - No News Is Not Good News
Apr 7, 2010
Biologics, Biosimilars & Data Exclusivity 101
Mar 24, 2010
Obamacare Good For Australian Biotechnology
Mar 23, 2010
Chemgenex: Dark Cloud, Silver Lining
Mar 16, 2010
Here's To Acrux, Its Investors & Aussie Biotech
Feb 16, 2010
Quattuordecim Dies Horribilis - Avexa, Chemgenex, CBio
Feb 9, 2010
Chemgenex, The FDA & Tough Questions
Feb 5, 2010
Tough Road Ahead For Avexa's ATC
Dec 14, 2009
Chemgenex's $137m Positive Signal
Nov 19, 2009
Progen - More Truce Than Resolution
Oct 7, 2009
Despite Price, Cytopia-YM Deal Good For Both
Oct 5, 2009
Crunch Time For Avexa's Apricitabine
Sept 25, 2009
Why Is Halcygen Buying Mayne Pharma?
Sept 9, 2009
Chemgenex ASX's Most Undervalued Biotech
Sept 3, 2009
Peplin Not A 5-Banger, Anymore
July 29, 2009
Dia-B, Pallane Fully Underwritten, Or Not?
July 22, 2009
Prima's $25.5 Convertible Note
July 14, 2009
Delist Or Not Delist?
July 3, 2009
Bioguide Brief: Progen - A New Train Coming?
June 30, 2009
Polartechnics, Fermiscan Strapped For Cash And The Wedding's Off
June 22, 2009
Dia-B, Pallane & A Flea In The Ear
May 13, 2009
April 20, 2009
Blessing The Polartechnics-Fermiscan Marriage
March 30, 2009
The Progen Prize Goes To .... Medigen?
March 11, 2009
Is That A Whiff Of Cash In The Air ?
March 9, 2009
Progen Kills Avexa Deal; Bioguide Brief: Progen Cops A Kicking
March 3, 2009
Stemcells Inc Buys Stem Cells For $7m; Bioguide Brief: Stem Cell Sells All But Shell
March 2, 2009
Arana And Under-10s Cricket
February 25, 2009
Who Contributes To Solagran's Share Price?
February 16, 2009
Thoratec Buys Heartware For $429m; Bioguide Brief: Deal Hurts Ventracor
February 6, 2009
Progen's Wedding Choices
January 28, 2009 Cytopia's Uncapped Bid For Progen; Bioguide Brief: Cytopia A Better Partner December 19, 2008
The Metabolic - Polynovo Deal
December 18, 2008
Fair Value IPOs, Cellscreen Direct
December 2, 2008
Genetic Technologies Frees Breast, Ovarian Cancer Tests; Bioguide: GTG & Corporate Philanthropy
November 14, 2008
Progen's Beerworth Review On The Money
Contact Marc using the form below